<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between 1980 and 1983, 317 bone-marrow (BM) aspirates from 63 cases of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) were studied with an in-vitro liquid culture monitoring system </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines were obtained in culture from 14 of 15 patients with cytologically positive marrow </plain></SENT>
<SENT sid="2" pm="."><plain>The in-vitro monitoring system was shown to be useful regardless of Epstein-Barr virus (EBV) status, clinical status of patients and cytogenetic anomalies (8 t(8;14) 2 t(8;22) 2 When BM was cytologically <z:mpath ids='MPATH_458'>normal</z:mpath> or suspect, i.e., less than 5% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells, the in-vitro monitoring system was shown to be more sensitive than cytological examination in 25 of 56 cases (44%) </plain></SENT>
<SENT sid="3" pm="."><plain>The sensitivity of the test is 1/100 000, i.e., 3 logs inferior to the level of detection by cytology </plain></SENT>
<SENT sid="4" pm="."><plain>When BM was harvested from <z:hpo ids='HP_0000001'>all</z:hpo> patients in complete remission after two months of chemotherapy, marrow purging proved not to be necessary (38/38 negative cultures); 7/10 of those patients will have been harvested to no purpose (no more than 30% with indication for autologous BM transplantation) </plain></SENT>
<SENT sid="5" pm="."><plain>When BM was harvested at relapse or in partial remission, the purging procedure was shown to be necessary in 9 of 16 cases (56%) </plain></SENT>
</text></document>